ORKA (Oruka Therapeutics) Float Percentage Of Total Shares Outstanding: 65.63% (As of Jul. 27, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ORKA Oruka Therapeutics Inc ORKA
14 GF Score
Price $92.15
! 3 Warning Signs
View Full Analysis

What is Oruka Therapeutics Float Percentage Of Total Shares Outstanding?

Oruka Therapeutics ORKA +0.29% 14 Float Percentage Of Total Shares Outstanding is 65.63% as of Jul. 27, 2026. GuruFocus rates ORKA with a GF Score™ of 14/100. The stock has 3 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Oruka Therapeutics's float shares is 39.58 Mil. Oruka Therapeutics's total shares outstanding is 60.31 Mil. Oruka Therapeutics's float percentage of total shares outstanding is 65.63%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Oruka Therapeutics's Insider Ownership is 2.14%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Oruka Therapeutics's Institutional Ownership is 91.77%.

ORKA
14GF Score
Oruka Therapeutics Inc ORKA
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oruka Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Oruka Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=39.58/60.31
=65.63%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 65.63% mean?
Oruka Therapeutics (ORKA) has a Float Percentage Of Total Shares Outstanding of 65.63% as of Jul. 27, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Oruka Therapeutics and its competitors.
Is Oruka Therapeutics' Float Percentage Of Total Shares Outstanding too high?
Oruka Therapeutics' current Float Percentage Of Total Shares Outstanding is 65.63%. Overall, Oruka Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Oruka Therapeutics' Float Percentage Of Total Shares Outstanding compare to DNTH and SRRK?
Oruka Therapeutics' Float Percentage Of Total Shares Outstanding of 65.63% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Oruka Therapeutics and its competitors. Oruka Therapeutics's current Float Percentage Of Total Shares Outstanding is 65.63%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oruka Therapeutics stock overvalued right now?
Oruka Therapeutics (ORKA) has a current Float Percentage Of Total Shares Outstanding of 65.63%. The current Float Percentage Of Total Shares Outstanding is 65.63%. Oruka Therapeutics' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Oruka Therapeutics (ORKA), the current Float Percentage Of Total Shares Outstanding is 65.63% as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oruka Therapeutics Business Description

Other Exchanges HQ1:Germany
Address 855 Oak Grove Avenue, Suite 100, Menlo Park, CA, USA, 94025
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.
14GF Score

Get the complete analysis for ORKA

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$92.15
Price